HBM Healthcare Investments AG
HBMN.SW
Swiss Exchange243.00
CHF
-1.00
- -
HBM Healthcare Investments AG
HBMN.SW
(Swiss Exchange)
Recent
price
243.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- HBM Healthcare Investments AG (SIX: HBMN) is a Swiss investment company focused on the global healthcare sector, managing a diversified portfolio of private and public companies in biotechnology, medical technology, diagnostics, therapeutics, and digital health; it engages in direct investments, fund-of-funds, growth capital, buyouts, and private investments in public equities (PIPEs), targeting startups through late-stage firms primarily in human medicine, drugs, pharma, biopharma, and related industries across North America, Europe, Asia Pacific including China and India. Founded through the 2005 acquisition of International BM Biomedicine by HBM Partners and listed on the SIX Swiss Exchange since 2008, the company is headquartered in Zug, Switzerland, with a net asset value exceeding CHF 2 billion and investments typically ranging from USD 5 million to USD 50 million per deal. Its portfolio, comprising around 25 core holdings with private companies at 30-35%, public at 48-50% (half formerly private), funds at 8-10%, and cash equivalents at 5-8%, emphasizes lead/co-lead roles in private financings, board seats, and exits via trade sales or IPOs; key investments include Swixx BioPharma and Swixx Healthcare (25.1% stake since 2017, largest holding with strong sales growth in emerging markets), Dren Bio, Numab, Mineralys Therapeutics, Upstream Bio, Cathay Biotech, Y-mAbs Therapeutics, and recent additions like Curevo and OneSource Speciality Pharma. Recent developments include a CHF 96 million half-year profit for the 2025/2026 financial year (NAV up 6.1% to CHF 251.78 despite currency headwinds), acquisitions boosting public portfolio value by CHF 132 million such as Genmab's USD 8 billion purchase of Merus (1.2% stake), Roche's up to USD 3.5 billion offer for 89Bio, SERB Pharma's USD 412 million buy of Y-mAbs, Johnson & Johnson's USD 1.25 billion acquisition of Yellow Jersey Therapeutics (Numab spin-off, CHF 59 million profit), and Sanofi's up to USD 1.9 billion deal for Dren Bio's DR-0201 program (USD 44 million cash inflow, stake retained); private portfolio highlights feature Swixx's multi-regional CNS distribution pact with Lundbeck A/S, Aculys Pharma's agreement with Viatris, Sai Life Sciences IPO (net proceeds CHF 34.3 million, 40% stake held), Upstream Bio IPO (USD 255 million raised), and new/share buyback programs approving cancellation of up to 10% of shares through 2028 alongside CHF 7.50 per share distribution (par value repayment CHF 2.60 plus dividend CHF 4.90). HBM Healthcare Investments maintains a disciplined strategy with partial USD hedges, selective profit-taking, and follow-on financings like CHF 19 million in existing privates, positioning it for M&A resurgence, clinical milestones, and capital market reopenings amid sector consolidation.